Financial Comparison: Zevra Therapeutics (ZVRA) vs. Its Competitors

Zevra Therapeutics (NASDAQ:ZVRA) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Zevra Therapeutics to related companies based on the strength of its dividends, profitability, risk, institutional ownership, analyst recommendations, earnings and valuation.

Institutional and Insider Ownership

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.7% of Zevra Therapeutics shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Zevra Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	52.80%	54.64%	37.84%
Zevra Therapeutics Competitors	-2,381.29%	-218.58%	-15.77%

Earnings and Valuation

This table compares Zevra Therapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zevra Therapeutics	$147.76 million	$83.23 million	9.48
Zevra Therapeutics Competitors	$5.42 billion	$3.22 billion	550.78

Zevra Therapeutics’ competitors have higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Zevra Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Zevra Therapeutics’ competitors have a beta of -4.10, meaning that their average share price is 510% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Zevra Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0	1	9	1	3.00
Zevra Therapeutics Competitors	7782	13874	25763	1035	2.41

Zevra Therapeutics presently has a consensus price target of $27.14, suggesting a potential upside of 140.65%. As a group, “Pharmaceuticals” companies have a potential upside of 26.44%. Given Zevra Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Zevra Therapeutics is more favorable than its competitors.

Summary

Zevra Therapeutics beats its competitors on 9 of the 13 factors compared.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.